Revisor Wealth Management LLC Has $819,000 Stake in AbbVie Inc. (NYSE:ABBV)

Revisor Wealth Management LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 68.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,909 shares of the company's stock after buying an additional 1,585 shares during the period. Revisor Wealth Management LLC's holdings in AbbVie were worth $819,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. LaFleur & Godfrey LLC grew its stake in AbbVie by 4.1% during the fourth quarter. LaFleur & Godfrey LLC now owns 79,396 shares of the company's stock valued at $14,109,000 after acquiring an additional 3,108 shares in the last quarter. Brighton Jones LLC lifted its position in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Fisher Asset Management LLC increased its stake in shares of AbbVie by 11.1% during the fourth quarter. Fisher Asset Management LLC now owns 43,233 shares of the company's stock valued at $7,683,000 after purchasing an additional 4,319 shares in the last quarter. Finally, Synergy Investment Management LLC purchased a new stake in shares of AbbVie in the fourth quarter worth $48,000. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Price Performance

ABBV stock traded down $1.25 during trading on Thursday, hitting $189.50. The company had a trading volume of 3,706,217 shares, compared to its average volume of 6,248,905. The business has a 50 day moving average of $187.12 and a 200 day moving average of $188.23. The firm has a market capitalization of $334.73 billion, a price-to-earnings ratio of 18.57, a P/E/G ratio of 1.27 and a beta of 0.48. AbbVie Inc. has a fifty-two week low of $163.63 and a fifty-two week high of $218.66. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The company had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same period in the previous year, the firm earned $2.31 earnings per share. AbbVie's revenue for the quarter was up 8.4% compared to the same quarter last year. As a group, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a dividend of $1.64 per share. The ex-dividend date is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.46%. AbbVie's dividend payout ratio is currently 279.15%.

Analyst Ratings Changes

Several research firms have recently weighed in on ABBV. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a research note on Monday, March 17th. Citigroup upped their price objective on AbbVie to $205.00 and gave the stock a "hold" rating in a research note on Wednesday, June 11th. BNP Paribas raised shares of AbbVie to a "hold" rating in a research note on Thursday, May 8th. Finally, Guggenheim increased their price objective on shares of AbbVie from $214.00 to $216.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $211.29.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.